Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

FDA
FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

May 29th 2024

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.

FDA
AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC

May 29th 2024

Sarah ES Leary, MD, MS, of Fred Hutchinson
Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma

May 28th 2024

Vikram M. Narayan, MD, of Emory University Hospital
Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

May 23rd 2024

Peter Fasching, MD
Guardant360 CDx Gains European Union Certification for Tumor Profiling in Solid Tumors

May 22nd 2024

More News